Novocure (NVCR) announced that Optune Lua has received a CE Mark for the treatment of adult patients with metastatic non-small cell lung cancer concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- NovoCure’s Optune Lua Gains CE Mark Approval
- NovoCure Ltd. (NVCR) Q1 Earnings Cheat Sheet
- Novocure price target lowered to $27 from $29 at Wedbush
- Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments Drive Buy Rating
- Novocure Reports Strong 2024 Revenue Growth